Radu Bolbos

Radu Bolbos

Auto-generated profile, based on publicly available information

Radu Bolbos

CERMEP, Lyon, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2016 in Scientific Reports
Verified
Journal Article
Open access
GBGuillaume Becker
Guillaume Becker
RBR. Bolbos
R. Bolbos
NCNicolas Costes
Nicolas Costes
JRJ. Redouté
J. Redouté
Adrian NEWMAN-TANCREDIAdrian NEWMAN-TANCREDI
Adrian NEWMAN-TANCREDI
LZL. Zimmer
L. Zimmer
Serotonin 1A (5-HT1A) receptors are involved in several physiological and pathological processes and constitute therefore an important therapeutic target. The recent pharmacological concept of biased agonism asserts that highly selective agonists can preferentially direct receptor signaling to specific intracellular responses, opening the possibility of drugs targeting a receptor subtype in specific brain regions. The present study brings additional support to this concept thanks to functional magnetic resonance imaging (7 Tesla-fMRI) in anaesthetized rats. Three 5-HT1A receptor agonists (8-OH-DPAT, F13714 and F15599) and one 5-HT1A receptor antagonist (MPPF) were compared in terms of influence on the brain blood oxygen level-dependent (BOLD) signal. Our study revealed for the first time contrasting BOLD signal patterns of biased agonists in comparison to a classical agonist and a silent antagonist. By providing functional information on the influence of pharmacological activation of 5-HT1A receptors in specific brain regions, this neuroimaging approach, translatable to the clinic, promises to be useful in exploring the new concept of biased agonism in neuropsychopharmacology.

1 December 2022 in Nanomedicine
Verified
Journal Article
Closed access
FLFrédéric Lerouge
Frédéric Lerouge
EOElodie Ong
Elodie Ong
HRHugo Rositi
Hugo Rositi
FMFrancis Mpambani
Francis Mpambani
LBLise-Prune Berner
Lise-Prune Berner
SPStephane Parola
Stephane Parola
Aim: To propose a new multimodal imaging agent targeting amyloid-β (Aβ) plaques in Alzheimer’s disease. Materials & methods: A new generation of hybrid contrast agents, based on gadolinium fluoride... Plain language summary The design and study of a new contrast agent targeting amyloid-β (Aβ) plaques in Alzheimer’s disease (AD) is proposed. Aβ plaques are the earliest pathological sign of AD, si... Tweetable abstract New multimodal contrast agent developed at University of Lyon: a functionalized gadolinium-based nanoparticle shows successful targeting of amyloid-β fibrils and in vivo detectio... Graphical abstract

25 March 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
MCMatthieu Chourrout
Matthieu Chourrout
HRHugo Rositi
Hugo Rositi
EOElodie Ong
Elodie Ong
VHViolaine Hubert
Violaine Hubert
APAlexandre Paccalet
Alexandre Paccalet
MWMarlène Wiart
Marlène Wiart
White-matter injury leads to severe functional loss in many neurological diseases. Myelin staining on histological samples is the most common technique to investigate white-matter fibers. However, tissue processing and sectioning may affect the reliability of 3D volumetric assessments. The purpose of this study was to propose an approach that enables myelin fibers to be mapped in the whole rodent brain with microscopic resolution and without the need for strenuous staining. With this aim, we coupled in-line (propagation-based) X-ray phase-contrast tomography (XPCT) to ethanol-induced brain sample dehydration. We here provide the proof-of-concept that this approach enhances myelinated axons in rodent and human brain tissue. In addition, we demonstrated that white-matter injuries could be detected and quantified with this approach, using three animal models: ischemic stroke, premature birth and multiple sclerosis. Furthermore, in analogy to diffusion tensor imaging (DTI), we retrieved fiber directions and DTI-like diffusion metrics from our XPCT data to quantitatively characterize white-matter microstructure. Finally, we showed that this non-destructive approach was compatible with subsequent complementary brain sample analysis by conventional histology. In-line XPCT might thus become a novel gold-standard for investigating white-matter injury in the intact brain. This is Part I of a series of two articles reporting the value of in-line XPCT for virtual histology of the brain; Part II shows how in-line XPCT enables the whole-brain 3D morphometric analysis of amyloid-β (Aβ) plaques. Highlights X-ray phase-contrast tomography (XPCT) enables myelin mapping of the whole brain XPCT detects and quantifies white-matter injuries in a range of diseases Fiber directions and anisotropy metrics can be retrieved from XPCT data XPCT is compatible with subsequent conventional histology of brain samples XPCT is a powerful virtual histology tool that requires minimal sample preparation

1 December 2007 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
XLX. Li
X. Li
RBR.I. Bolbos
R.I. Bolbos
KLK.J. Lin
K.J. Lin
BMB.C. Ma
B.C. Ma
MRMichael D. Ries
Michael D. Ries
SMSharmila Majumdar
Sharmila Majumdar

6 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SBSimone Beretta
Simone Beretta
DCDavide Carone
Davide Carone
TCTae-Hee Cho
Tae-Hee Cho
MVMartina Viganò
Martina Viganò
SDSusanna Diamanti
Susanna Diamanti
FCFabien Chauveau
Fabien Chauveau
We investigated the therapeutic effect of head down positioning at −15° (head down tilt; HDT15) on cerebral collateral flow and infarct growth in a rat model of large vessel occlusion (LVO) stroke, using multi-modal MRI. Twenty-eight Wistar rats were randomly assigned to HDT15 or flat position for 60 minutes, starting 30 minutes after occlusion of the middle cerebral artery, followed by reperfusion. The perfusion shift analysis, comparing post- versus pre-treatment voxel-level changes in time-to-peak perfusion maps, showed a significant increase in cerebral perfusion in the HDT15 group (common odds ratio 1.50; 95% CI 1.41-1.60; p < 0.0001), but not in the flat group (common odds ratio 0.97; 95% CI 0.92-1.03; p = 0.3503). Infarct growth at 24 hours was + 31.4% in the flat group (343 versus 250 mm 3 ; 95% CI 2.4 to 165.1; p = 0.0447) and + 15.4% in the HDT15 group (224 versus 192 mm 3 ; 95% CI -26.9 to 85.9; p = 0.2272). Our findings indicate that HDT15 acutely increases cerebral perfusion in LVO acute ischemic stroke and provides a tissue-saving effect before recanalization. Further research is needed to develop HDT15 as an emergency therapy to acutely increase collateral flow in ischemic stroke prior to recanalization therapy.